# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k080381   
B. Purpose for Submission: New Device   
C. Measurand: Methamphetamine   
D. Type of Test: Qualitative Enzyme Immunoassay   
E. Applicant: Quest Diagnostics   
F. Proprietary and Established Names: Quest Diagnostics Methamphetamine Micro-Plate EIA Quest Diagnostics Methamphetamine Micro-Plate EIA Calibrators Quest Diagnostics Methamphetamine Micro-Plate EIA Controls

# G. Regulatory Information:

1. Regulation section:

21 CFR 862.3610 Methamphetamine Micro-Plate EIA   
21 CFR $\$ 862.3200$ , Clinical toxicology calibrator   
21 CFR $\ S 8 6 2 . 3 2 8 0$ , Clinical toxicology control material

2. Classification:

Class II (assay and calibrators) Class I, reserved (control)

3. Product code:

LAF DLJ LAS

4. Panel: 91 Toxicology

# H. Intended Use:

1. Intended use(s): See indications for use section below.

2. Indication(s) for use:

The Quest Diagnostics Methamphetamine Micro-Plate EIA is intended for the qualitative detection of Methamphetamine in oral fluid collected with the OrasureTM Oral Specimen Collection Device. It is a screen test with a cutoff of 40 $\mathrm { n g / m l }$ .

The Quest Diagnostics Methamphetamine Micro-Plate EIA provides only a preliminary result. Clinical consideration and professional judgment must be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain confirmed analytical results a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method.

The Quest Diagnostics Methamphetamine Micro-Plate EIA Calibrators are intended for medical purposes and for use only with the Quest Diagnostics Methamphetamine Micro-Plate EIA to establish points of reference that are used in the determination of values in the measurement of methamphetamine in oral fluid samples collected with OraSureTM Oral Specimen Collection Device.

The Quest Diagnostics Methamphetamine Micro-Plate EIA Controls are intended for use as an assay quality control matrix to monitor the precision and accuracy of the laboratory testing procedures for methamphetamine in oral fluid samples collected with OraSureTM Oral Specimen Collection Device.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements:

A plate reader is required. All performance for this device was conducted on the Titertek Multiskan MCC/340 plate reader.

# I. Device Description:

The Quest Diagnostics Methamphetamine Micro-Plate EIA kit contains EIA plates, conjugates, conjugate diluents, substrate, stop solution, wash solution, calibrators and controls. The EIA plates contain antiserum to methamphetamine immobilized on a polystyrene plate. The conjugate is composed of horseradish peroxides labeled with methamphetamine in buffer with protein stabilizers. The conjugate diluent is tris buffer containing BSA. The dual level calibrators’ concentrations are $0 \mathrm { n g / m L }$ and $4 0 \mathrm { n g / m l }$ . The tri-level controls concentrations are $1 0 ~ \mathrm { n g / m L }$ , $2 0 ~ \mathrm { n g / m L }$ and $8 0 ~ \mathrm { n g / m l }$ MAP. Both calibrators and controls are included with the device. The OraSure collection device is not included with the device but can be purchased from Quest or OraSure.

# J. Substantial Equivalence Information:

1. Predicate device name(s): OraSure Methamphetamine Intercept Microplate EIA

2. Predicate K number(s): k993208

3. Comparison with predicate:

<table><tr><td colspan="3">Similarities</td></tr><tr><td>Item</td><td>Device</td><td>Predicate</td></tr><tr><td>Indications for use</td><td>Qualitative detection of methamphetamine in human saliva specimens collected with the OraSure oral fluid collection device</td><td>Same</td></tr><tr><td>Methodology</td><td>Microplate EIA</td><td>Same</td></tr><tr><td>Cutoff</td><td>40 ng/ml</td><td>Same</td></tr></table>

<table><tr><td colspan="3">Differences</td></tr><tr><td>Item</td><td>Device</td><td>Predicate</td></tr><tr><td>Controls/calibrators</td><td>5 levels in the same base as calibrator. Calibrator values: 0 and 40 ng/ml. Controls: 10, 20 and 80 ng/ml.</td><td>4 levels in the same base as calibrators (0,20, 40, and 80 ng/ml)</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None referenced.

# L. Test Principle:

The Quest Diagnostics Methamphetamine Micro-Plate EIA is a competitive immunoassay for the qualitative determination of Methamphetamine in oral fluid specimens. Methamphetamine in oral fluid and the methamphetamine in the enzyme conjugate compete for the limited binding sites of antibody fixed to a microtiter plate. If little or no methamphetamine is present in the specimen, more enzyme labeled methamphetamine will be bound by methamphetamine antibody. If a large or significant amount of methamphetamine is present in the specimen, less enzyme labeled methamphetamine will be bound to the plate, reducing overall activity and signal level. The absorbance produced is inversely proportional to the amount of methamphetamine in the specimen, calibrator or control.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision studies were performed on 5 negative patient samples by spiking with 0, 10, 20, 30, 40, 50, 60 and $7 0 \mathrm { n g / m l }$ of methamphetamine; drug concentrations were confirmed by GC/MS. These concentrations correspond to 0, 25, 50, 75, 100, 125, 150 and $1 7 5 \%$ of the cutoff. Testing was performed in replicates of 4 for 10 days for 8 concentrations. The results are shown in the table below.

Quest Diagnostics Methamphetamine Micro-Plate EIA Intra-Assay $\% \mathrm { C V }$ Results   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>SP 1</td><td rowspan=1 colspan=1>SP 2</td><td rowspan=1 colspan=1>SP 3</td><td rowspan=1 colspan=1>SP 4</td><td rowspan=1 colspan=1>SP 5</td><td rowspan=1 colspan=1>SP 6</td><td rowspan=1 colspan=1>SP 7</td><td rowspan=1 colspan=1>SP 8</td></tr><tr><td rowspan=1 colspan=1>MAP (ng/ml)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>Mean OD</td><td rowspan=1 colspan=1>2.498</td><td rowspan=1 colspan=1>0.946</td><td rowspan=1 colspan=1>0.694</td><td rowspan=1 colspan=1>0.576</td><td rowspan=1 colspan=1>0.490</td><td rowspan=1 colspan=1>0.442</td><td rowspan=1 colspan=1>0.399</td><td rowspan=1 colspan=1>0.375</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Agreement</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>65.5%</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100%</td></tr></table>

b. Linearity/assay reportable range:

Not applicable. This assay is intended for qualitative use.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

All calibrator and control stock solutions are prepared from commercially available solutions. The methamphetamine concentrations of the stock solution were determined by GC/MS. From the stock solution, a secondary stock solution was prepared gravimetrically. The positive control was prepared from the secondary stock. The cutoff calibrator, negative control and low negative control were prepared by serial dilutions of the positive controls. All of the components were confirmed by GC/MS.

Claimed shelf-life of the Quest Diagnostics Methamphetamine Micro-Plate EIA calibrator and controls is 110 days for when stored at 2-8 C. The Quest Diagnostics Methamphetamine Micro-Plate EIA reagents are stable at room temperature (21-25 C) for 30 days. Real-time studies are ongoing.

The stability of methamphetamine in the OraSure collection device was determined by taking a pool of negative oral fluid samples spiked at ten different concentrations. The samples were run at day one with the EIA device and leftover samples were stored at room temperature $( 2 1 - 2 5 ~ ^ { \circ } \mathrm { C } )$ for 28 days. Those stored samples were tested again with the EIA device for direct comparison with day one results. The result support the sponsor’s claim that saliva specimens collected with the OraSure collection devices remain stable for at least 28 days when stored at 21 $- 2 5 ~ ^ { \circ } C$ .

Shipment stability was assessed by spiking eight negative neat saliva samples (in pairs) with various concentrations of methamphetamine. One set was shipped within the US and returned. The shipped collection devices testing results were compared to that of the non-shipped collection device. The results showed that shipping did not after the performance of the Quest Diagnostics Methamphetamine Micro-Plate EIA device and that the results were identical for both the shipped and non-shipped devices.

# d. Detection limit:

See the precision/reproducibility section above for performance around the stated cutoff concentration.

# e. Analytical specificity:

Cross reactivity of structurally similar compounds was determined by spiking concentrations of different drugs into negative oral fluid. Fourteen members of the amphetamine family, and structurally similar compounds, (see table

below) were tested for cross reactivity to the Quest Diagnostics Methamphetamine Micro-Plate EIA using d-Methamphetamine as the $100 \%$ reference. A negative pool was spiked with $4 { , } 0 0 0 \mathrm { n g / m l }$ of each compound; three substances (MDMA, PMA and PMMA) tested positive at that level were tested with further dilutions until a negative result was produced. The Quest Diagnostics EIA produced the following cross-reactivity results methamphetamine.

Quest Diagnostics Methamphetamine Micro-Plate EIA Cross reactivity data   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Test Conc. (ng/ml)</td><td rowspan=1 colspan=1>Cross Reactivity</td></tr><tr><td rowspan=1 colspan=1>Phentermine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>Phenylpropanolamine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>Ephedrine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>Pseudoephedrine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>S-Amphetamine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt; 1.0%</td></tr><tr><td rowspan=1 colspan=1>MDMA</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>117.3%</td></tr><tr><td rowspan=1 colspan=1>MDA</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt; 1.0%</td></tr><tr><td rowspan=1 colspan=1>R-Methamphetamine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>R-Amphetamine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>Ranitidine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>Mephentermine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>Fenfluramine</td><td rowspan=1 colspan=1>4000</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>PMA</td><td rowspan=1 colspan=1>2500</td><td rowspan=1 colspan=1>1.7 %</td></tr><tr><td rowspan=1 colspan=1>PMMA</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>217.5%</td></tr></table>

MDMA- PMA dose response curve was used to determine its MAP equivalent concentration. Based on this data (shown below), the cross-reactivity of MDMA with the Quest Diagnostics EIA was determined to be $1 1 7 . 3 \%$ .

MDMA ODs   

<table><tr><td>Tested Conc. ng/ml</td><td>P/N Result</td></tr><tr><td>0</td><td>N</td></tr><tr><td>15</td><td>N</td></tr><tr><td>20</td><td>N</td></tr><tr><td>25</td><td>N</td></tr><tr><td>30</td><td>N</td></tr><tr><td>35</td><td>P</td></tr><tr><td>40</td><td>P</td></tr></table>

PMMA-the MAP dose response curve was used to determine MAP equivalent concentration for the PMMA. Based on this data (shown below), the crossreactivity of PMMA with the Quest Diagnostics EIA is $2 1 7 . 5 \%$

PMMA ODs   

<table><tr><td>Tested Conc. ng/ml</td><td>P/N Result</td></tr><tr><td>0</td><td>N</td></tr><tr><td>15</td><td>N</td></tr><tr><td>20</td><td>P</td></tr><tr><td>25</td><td>P</td></tr><tr><td>40</td><td>P</td></tr></table>

PMA- the MAP dose response curve was used to determine MAP equivalent concentration for the PMA. Based on this data, the cross-reactivity of PMA with the Quest Diagnostics EIA is $1 . 7 \%$

PMA ODs   

<table><tr><td>Tested Conc. ng/ml</td><td>P/N Result</td></tr><tr><td>0</td><td>N</td></tr><tr><td>1500</td><td>N</td></tr><tr><td>2000</td><td>N</td></tr><tr><td>2500</td><td>P</td></tr><tr><td>3000</td><td>P</td></tr><tr><td>3500</td><td>P</td></tr><tr><td>4000</td><td>P</td></tr></table>

Interference of various potentially cross-reacting or interfering commonly used substances was evaluated with the Quest Diagnostics Methamphetamine Micro-Plate EIA device. A positive $( 6 0 \mathrm { n g / m l } )$ and a negative base $( 2 0 \mathrm { n g / m l } )$ was created by spiking a negative pool collected with the OraSure device with methamphetamine. Ten $\mathrm { { u g / m l } }$ of each of the test compounds listed in the package insert were spiked into the negative and positive base pools and none of the 64 tested compounds exhibited any negative or positive interference with the assay.

Endogenous substances were tested for interference with the Quest Diagnostics Methamphetamine Micro-Plate EIA. Pools of the OraSure saliva specimens that tested negative to the device were divided and one was spiked with $8 0 ~ \mathrm { n g / m l }$ of methamphetamine. Human Serum Albumin (HSA), bilirubin, ascorbic acid and hemoglobin was tested at varying concentrations and run in duplicate with the Quest Diagnostics Methamphetamine MicroPlate EIA. The results did not show any negative or positive interference with the assay for bilirubin up to $5 0 \mathrm { m g / m l }$ , ascorbic acid up to $1 0 { , } 0 0 0 \ \mathrm { m g / ; L }$ , hemoglobin up to $1 0 0 0 \mathrm { m g / L }$ and HAS up to $5 0 0 0 , \mathrm { m g / L }$ .

Commonly encountered consumable substances (along with blood and distilled water) was evaluated with the Quest Diagnostics Methamphetamine Micro-Plate EIA device. The sponsor reported no interference (positive or negative) from the substances shown below with the device.

Consumable Substance Interference   

<table><tr><td rowspan=2 colspan=1>Substance</td><td rowspan=2 colspan=1>TestConc.</td><td rowspan=1 colspan=2>Pos./Neg.</td></tr><tr><td rowspan=1 colspan=1>Neg. Poolwith 0ng/mlMAP</td><td rowspan=1 colspan=1>Neg. Poolwith 80ng/ml MAP</td></tr><tr><td rowspan=1 colspan=1>Sucrose</td><td rowspan=1 colspan=1>3.3% w/v</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Cranberry Juice</td><td rowspan=1 colspan=1>33% v/v</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Baking Soda</td><td rowspan=1 colspan=1>3.3% w/v</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Orange Juice</td><td rowspan=1 colspan=1>33% v/v</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Cola</td><td rowspan=1 colspan=1>33% v/v</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Cough Syrup</td><td rowspan=1 colspan=1>33% v/v</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Antiseptic MouthWash</td><td rowspan=1 colspan=1>33% v/v</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Toothpaste</td><td rowspan=1 colspan=1>5% w/v</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Dental Adhesive A</td><td rowspan=1 colspan=1>4 mg/ml</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>Dental Adhesive B</td><td rowspan=1 colspan=1>4 mg/ml</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>DI Water</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Blood from 4different patients</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>0 ng/ml</td><td rowspan=1 colspan=1>80ng/ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>0 ng/ml</td><td rowspan=1 colspan=1>80 ng/ml</td></tr><tr><td rowspan=1 colspan=1>100% Sample(UnalteredSample Pool) -control</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1% Blood #199% UnalteredSample Pool (v/v)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>50% Sample50%Water (v/v)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>1% Blood #299% UnalteredSample Pool (v/v)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>25% Sample75% Water (v/v)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>1% Blood #399% UnalteredSample Pool (v/v)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr><tr><td rowspan=1 colspan=1>10% Sample90% Water (v/v)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>1% Blood #499% UnalteredSample Pool (v/v)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>P</td></tr></table>

$f .$ Assay cut-off:

The sponsor conducted a cutoff study in which the cutoff calibrator was tested in triplicate by GC/MS to verify their chosen cutoff of $4 0 \mathrm { n g / m l }$ . Five aliquots of pooled negative patient specimens were spiked with 0, 20, 30, 50 and 60 $\mathrm { n g / m l }$ methamphetamine. The concentrations were confirmed by GC/MS and were run in replicates of 20 with the Quest Diagnostics Methamphetamine Micro-Plate EIA. The results shown below support the sponsor chosen cutoff of $4 0 ~ \mathrm { n g / m L }$ .

Cutoff Challenge Results   

<table><tr><td rowspan=1 colspan=1>Concentration(ng/ml)</td><td rowspan=1 colspan=1>Number</td><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24 Negative</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24 Negative</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>7 Negative</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24 Positive</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24 Positive</td><td rowspan=1 colspan=1>100</td></tr></table>

2. Comparison studies:

a. Method comparison with predicate device:

One-hundred patient samples were collected in accordance with the OraSure collection device test insert by trained professionals from Quest diagnostics. Specimens were stored at $2 { - } 8 \ ^ { \circ } \mathrm { C }$ prior to testing. Specimen results from the Quest Diagnostics Methamphetamine Micro-Plate EIA device was compared to GC/MS reference method (with $4 0 \mathrm { n g / m l }$ as the cutoff).

# Quest EIA v. GC/MS

<table><tr><td rowspan=3 colspan=1>A total of 100samples weretested</td><td rowspan=1 colspan=6>Methamphetamine Conc. by GC/MS (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>0 to-50% C/O</td><td rowspan=1 colspan=1>-50%C/O toC/O</td><td rowspan=1 colspan=1>C/O to+50%C/0</td><td rowspan=1 colspan=1>&gt; 50%C/O</td><td rowspan=2 colspan=1>OverallAgreement</td></tr><tr><td rowspan=1 colspan=1>Conc.(ng/ml)</td><td rowspan=1 colspan=1>&lt;20</td><td rowspan=1 colspan=1>20-39</td><td rowspan=1 colspan=1>40.0-60</td><td rowspan=1 colspan=1>&gt;60</td></tr><tr><td rowspan=2 colspan=1>Quest EIA(Screen)</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>6{}$</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>81.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>97.8%</td></tr><tr><td rowspan=1 colspan=2>Agreement:</td><td rowspan=1 colspan=1>91.1%</td><td rowspan=1 colspan=1>33.3%</td><td rowspan=1 colspan=1>91.7%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>89.0%</td></tr></table>

1 All four specimens were tested by GC/MS and contain MDMA, a compound know to produce positive results with the Quest EIA at $3 5 \mathrm { n g / m l }$ (cross-reactivity of $1 1 7 . 3 \%$ ). Three (3) specimens contained more than $3 5 ~ \mathrm { { n g / m l } }$ MDMA (38, 100, $4 8 0 \mathrm { n g / m l }$ respectively). One specimen contained $3 1 ~ \mathrm { n g / m l }$ MDMA and $1 6 ~ \mathrm { { n g / m l } }$ Methamphetamine. The combined reactivities produced a positive result with the Quest EIA, as would be expected given the cross-reactivity rate for MDMA.

2 Among these six false positive specimens by EIA, all had Methamphetamine concentrations in the range of - $50 \%$ to Cutoff (31, 31, 25, 23, 33, $3 5 \mathrm { n g / m l }$ respectively). Two specimens also had significant amounts MDMA (32 & 135 $\mathrm { n g / m l }$ respectively).

3 This sample contained $4 5 \mathrm { n g / m l }$ of MAP.

b. Matrix comparison:

Not applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
$b$ . Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.